ImmuCell Corporation Construction in Progress Expenditures Incurred but Not yet Paid
ImmuCell Corporation (ICCC) reported Construction in Progress Expenditures Incurred but Not yet Paid of $341.68 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid · last filed 2023-03-29
- ImmuCell Corporation construction in progress expenditures incurred but not yet paid for fiscal 2022 was $341.68K.
| Period end | Construction in Progress Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2022-12-31 | $341.68K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |